The omega-3 and Nano-curcumin effects on vascular cell adhesion molecule (VCAM) in episodic migraine patients: a randomized clinical trial

BMC Research Notes

Mina Abdolahi¹  Hamed Abdollahi²  Abolghasem yousefi²  Mohsen Sedighiyan³  Mahmoud Djalali³  Amir Shayegan rad³  Elmira Karimi⁴  Goli Siri⁵  Farahnaz Salehinia⁵  Behzad Asanjarani⁵  Mostafa Badeli⁶  Niyoosha Yoosefi⁷  Payam Sarraf⁸  Abbas Tafakhori⁸ 

[1] Amir Alam Hospital Complexes, Tehran University of Medical Sciences, Sa’adi Street, Tehran, Iran;Department of Anesthesiology, Amir Alam Hospital Complexes, Tehran University of Medical Sciences, Sa’adi Street, Tehran, Iran;Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, PO Box: 14155-6446, Poursina Street, Tehran, Iran;Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Poursina Street, Tehran, Iran;Department of Internal Medicine, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran;Department of Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Poursina Street, Tehran, Iran;Honours Cellular Anatomical Physiology, University of British Columbia, Vancouver, BC, Canada;Iranian Centre of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran;Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran;

关键词: Migraine;    Vascular cell adhesion molecule;    Gene expression;    Serum concentration;    Omega-3;    Nanocurcumin;   

DOI  :  10.1186/s13104-021-05700-x

来源: Springer

【 摘 要 】

ObjectiveThe purpose of this clinical trial was to examine the effect of omega-3 fatty acids (W-3 FAs), nanocurcumin and their combination on serum levels and gene expression of VCAM in patients with episodic migraine.ResultsIn this study, 80 patients were randomly divided in to 4 groups to receive for 2 months. Both serum levels and gene expression of VCAM showed remarkable decreases after single W-3 and after combined W-3 and nanocurcumin interventions. However, a borderline significant change and no remarkable change were observed after single nanocurcumin supplementation and in control group, respectively. While a significant difference between study groups in VCAM concentrations existed, there was no meaningful difference in VCAM gene expression among groups. It appears that the W-3 and combined W-3 and nanocurcumin can relieve VCAM serum level and its gene expression in patients with episodic migraine. Moreover, the combination of W-3 with nanocurcumin might cause more significant declines in VCAM level in the serum of migraine patients than when W-3 is administered alone.Trial Registration: This study was registered in Iranian Registry of Clinical Trials (IRCT) with ID number: NCT02532023.

【 授权许可】

CC BY